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Abstract
To compare the management and outcome of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in patients known to be
MRSA-colonized/infected (C-patients) with the management and outcome in those not known to be colonized/infected (NC-patients), we
conducted a 10-year retrospective review of MRSA bacteraemia in an adult tertiary hospital. Clinical data were obtained by chart review,
and mortality data from linked databases. Prior MRSA colonization/infection status was available to treating clinicians at the time of the
bacteraemia as a ‘Micro-Alert’ tag on the patient’s labels, in medical charts, and in electronic information systems. C-patients accounted
for 35.4% of all MRSA bacteraemia episodes. C-patients were more likely to be indigenous, to be diabetic, or to have a history of
previous S. aureus infection. Markers of illness severity (Simpliﬁed Acute Physiology Score (SAPS)-II, need for admission to the
intensive-care unit, length of stay, and metastatic seeding) were similar in both groups. Empirical therapy included a glycopeptide in 49.3%
of C-patients vs. 18.9% of NC-patients (p <0.01), and contained an antibiotic to which the MRSA isolate tested susceptible in vitro in
56.7% of C-patients vs. 45.1% of NC-patients (p 0.13). All-cause 7-day and 30-day mortality were 7.5% vs. 18.9% (p 0.04), and 22.4% vs.
31.1% (p 0.20), in the C-patient and NC-patient groups, respectively. Knowing MRSA colonization status was signiﬁcantly associated with
lower 30-day mortality in Cox regression analysis (p <0.01). These data suggest that mortality from MRSA bacteraemia is lower in
C-patients, which may reﬂect the earlier use of glycopeptides. The low use of empirical glycopeptides in septic patients known to be
previously MRSA-colonized/infected may represent a missed opportunity for infection control to positively impact on clinical
management.
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Introduction
Staphylococcus aureus bacteraemia is associated with signiﬁcant
morbidity and mortality [1,2]. Meta-analyses have shown that
patients with methicillin-resistant S. aureus (MRSA) bactera-
emia are more likely to have an unfavourable outcome than
those with methicillin-susceptible S. aureus bacteraemia [3,4].
This difference may be partly attributable to the administration
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of antibiotics without in vitro activity against MRSA while
susceptibility results are pending; inappropriate therapy given
within the ﬁrst 45–8 h after the blood culture was taken has
been shown to be an independent predictor of mortality in
MRSA bacteraemia [5,6].
S. aureus colonization often precedes invasive infection [7].
A study on the long-term risk of MRSA colonization has shown
that 29% of patients with previous MRSA colonization develop
an infection, occurring on average 102 days after the initial
isolation of MRSA [8]. Although awareness of prior MRSA
colonization status could impact on patient treatment for
invasive MRSA infection, data on MRSA colonization status are
primarily collated and used for infection control purposes, and
are not always available to the treating physician when a
patient presents to hospital.
In Western Australia, demographic data, together with
outpatient and inpatient visits of patients attending public
hospitals, are recorded in a common database. Known carriers
of antibiotic-resistant organisms are recorded in this database
(Micro-Alert), which helps infection control staff to implement
appropriate measures to prevent MRSA transmission.
In this study, we aimed to determine whether information
on prior MRSA infection/colonization status (provided by the
Micro-Alert system and available to clinicians) impacted on the
management and outcome of patients with MRSA bacteraemia.
Materials and Methods
Case ascertainment and clinical data collection
We conducted a 10-year retrospective review of all episodes of
MRSA bacteraemia that occurred in a 955-bed adult teaching
hospital between June 1997 and June 2007, as previously
described [1]. Episodes were identiﬁed by use of the Microbi-
ology Department’s database. Demographic and clinical data
were obtained from chart review. Severity of illness at the time
of the bacteraemia was evaluated according to the Simpliﬁed
Acute Physiology Score (SAPS)-II [9], intensive-care unit (ICU)
admission, duration of fever, bacteraemia with positive blood
culture for >24 h, and the presence of infective endocarditis (as
deﬁned in [10]) or metastatic infection. Additionally, length of
hospital stay and time from the ﬁrst positive blood culture to
discharge were determined. All-cause mortality at 7 days and
30 days following the day of MRSA bacteraemia were deter-
mined from clinical information systems, which are data-linked
to the Western Australian Registry of Deaths.
Deﬁnitions
An episode of MRSA bacteraemia was deﬁned as culture of the
organism in one or more sets of blood cultures. If a patient had
more than one episode of MRSA bacteraemia, only the ﬁrst
episode was included in the analysis.
Colonization status
In our centre, systematic MRSA screening is performed only
on patients at high risk of importing MRSA from another
institution, or those in whom MRSA infection is particularly
troublesome, such as those undergoing cardiothoracic/
orthopaedic surgery or patients in the bone marrow
transplant unit or ICU. MRSA screening is performed
with a nasal swab and a swab of any wound, ulcer, or skin
lesion.
Since 1997, all patients and healthcare workers colonized or
infected with MRSA have been notiﬁed to the Western
Australian Department of Health, and MRSA isolates have
been referred to the Australian Collaborating Centre for
Enterococcus and Staphylococcus Species (ACCESS) Typing
and Research. A Micro-Alert tag is then electronically added to
the patient identiﬁcation label, which is used on subsequent
public hospital admissions. The Micro-Alert label remains as
long as the patient is not successfully decolonized with
documentation of two negative sets of swabs (nose, throat,
and perineum) in the absence of ongoing wounds, invasive
devices, and/or antimicrobial therapy. Decolonization is per-
formed on patients with MRSA colonization prior to elective
orthopaedic or cardiovascular surgery, and on patients trans-
ferred to our rehabilitation facility, to avoid transmission via
shared physiotherapy equipment.
Episodes of MRSA bacteraemia were considered as occur-
ring in known colonized patients (C-patients) if patients were
‘Micro-Alerted’ at least 2 days prior to the positive blood
culture. All other patients were considered as not known to
be colonized (NC-patients).
S. aureus identiﬁcation and susceptibility testing were per-
formed as previously described [1].
Antimicrobial therapy
Details of antimicrobial therapy administered were obtained
from medication charts. Empirical antimicrobial therapy (i.e.
therapy administered prior to the susceptibility results being
available) was considered to be ‘active’ if the MRSA isolated
was susceptible in vitro to one or more of the agents that were
administered. This included regimens that were composed of
an agent or agents not generally recommended for the
treatment of MRSA bacteraemia at our institution (e.g.
ciproﬂoxacin, gentamicin, doxycycline, erythromycin, clinda-
mycin, and azithromycin). The absence of a routine D-test for
the detection of inducible resistance to clindamycin did not
have any impact, as no patients were treated with clindamycin
as the sole active agent. Empirical therapy was considered to
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be ‘inactive’ if it was composed of an agent or agents without
in vitro anti-MRSA activity.
Statistical methods
Means were compared by use of Student’s t-test or the Mann–
Whitney non-parametric test when appropriate. Percentages
were compared by use of Pearson’s v2-test or Fisher’s exact
test. Groups were compared by means of the log-rank test. A
p-value of <0.05 was considered to be signiﬁcant. A series of
univariate logistic regression models with 30-day mortality as
the dependent variable were used to identify potential predic-
tors of mortality risk. The variables chosen were those with at
least 90% non-missing observations and a univariate p -value of
<0.1. The variables chosen for inclusion on the basis of
univariate analysis were nosocomial infection, SAPS-II, meta-
static seeding, ‘active’ empirical treatment, age, dialysis, and
Aboriginal heritage. Because of the relatively low number of
episodes, the variables entered into the Cox regression model
were limited to the most signiﬁcant. The validity of the
proportional hazards model was determined with the phtest
based on Schoenfeld residuals. All statistical analyses were
performed in SPSS 18.0 for Windows (SPSS, Chicago, IL, USA)
and STATA (Version 12; StataCorp LP, College Station, TX,
USA).
This study was approved by our institution’s ethics com-
mittee.
Results
Two hundred and four episodes of MRSA bacteraemia in 194
patients were identiﬁed over the study period. Charts were
obtainable for 189 patients (97.4%) with 197 episodes of
bacteraemia (96.6%). Eight episodes of bacteraemia were
removed because they occurred in patients already in the
database. All further analyses refer to these 189 episodes.
Sixty-seven episodes of MRSA bacteraemia (35.4%) occurred
in C-patients, and 122 (64.6%) in NC-patients.
Demographics and risk factors
Demographic data and risk factors are shown in Table 1.
Diabetes and dialysis were more frequent in the C-patient
group than in the NC-patient group (respectively: 32/67
(47.8%) vs. 33/122 (27.0%), p <0.01; and 16/67 (23.9%) vs. 9/
122 (7.4%), p <0.01). Aboriginal/Torres Strait islander ethnic-
ity was also more frequent in the C-patient group (19/67
(28.4%) vs. 17/122 (3.9%), p 0.01). As expected, hospitaliza-
tion/outpatient clinic attendance in the past year and a history
of previous invasive S. aureus infection were also more
frequent in the C-patient group (Table 1).
Source of bacteraemia
When identiﬁed, the source of MRSA bacteraemia was similar
between C-patients and NC-patients, with a predominance of
catheter-related bacteraemia, followed by skin/soft tissue,
bones/joints and the respiratory tract as the clinical source of
the bacteraemia. No source for the bacteraemia was identiﬁed
in seven of 67 (10.4%) C-patients, and in 30 of 122 (26.4%)
NC-patients (p 0.02) (Table 1).
Severity of infection
SAPS-II was statistically not different between C-patients and
NC-patients (median 37 (range 12–77) vs. 41 (range 14–84),
p 0.08). There were no signiﬁcant differences between the two
groups regarding ICU admission (8/67 (11.9%) vs. 13/122
(10.7%), p 0.79), length of stay (median 21 days (range 0–137
days) vs. 21 days (range 0–209 days), p 0.79, in C-patients and
NC-patients, respectively) or the percentage of patients with
positive blood culture for >24 h (15/28 (53.6%) vs. 31/58
(53.4%), p 0.99). Furthermore, the duration of fever (2 days
(range 0–19 days) vs. 2 days (range 0–33 days), p 0.32), the
presence of endocarditis (2/67 (3.0%) vs. 8/122 (6.6%), p 0.29)
and the presence of metastatic seeding (7/67 (10.4%) vs. 21/122
(17.2%), p 0.21) were similar between C-patients and NC-
patients.
TABLE 1. Demographics, risk factors and source of bacter-
aemia
Known
colonization
(C-patients)
No known
colonization
(NC-patients) p
No. (%) 67 (35.4) 122 (63.1)
Male, no. (%) 35 (52.2) 77 (68.8) 0.15
Median age in years (range) 62 (12–95) 68.5 (16–96) 0.27
Aboriginal/Torres
Strait islander, no. (%)
19 (28.4) 17 (13.9) 0.02
Diabetes, no. (%) 32 (47.8) 33 (27.0) <0.01
Intravenous drug use, no. (%) 0 4 (3.3) 0.13
Solid or haematological
malignancy, no. (%)
13 (19.4) 26 (21.3) 0.76
Immunosuppressive treatment,
no. (%)
5 (7.53) 14 (11.5) 0.38
Previous invasive Staphylococcus
aureus infection, no. (%)
21 (31.3) 9 (7.4) <0.01
Dermatological condition, no. (%) 5 (7.5) 4 (3.3) 0.20
Hospitalization/clinic in past year,
no. (%)
49 (73.1) 58 (47.5) <0.01
Residence in long-term-healthcare
facility, no. (%)
17 (25.4) 31 (25.4) 0.99
Human immunodeﬁciency virus
infection, no. (%)
1 (1.5) 1 (0.8) 0.67
Dialysis, no. (%) 16 (23.9) 9 (7.4) <0.01
Primary bacteraemiaa, no. (%) 7 (10.4) 30 (26.4) 0.02
Skin/soft tissue infection, no. (%) 15 (22.4) 19 (15.6) 0.24
Intravascular catheter, no. (%) 18 (26.9) 31 (25.4) 0.83
Bone/joint infection, no. (%) 10 (14.9) 11 (9.0) 0.22
Respiratory tract infection, no. (%) 4 (6.0) 17 (13.9) 0.10
Digestive tract infection, no. (%) 3 (4.5) 1 (0.8) 0.10
Endovascular infection, no. (%) 4 (6.0) 5 (4.1) 0.56
Intravenous drug use, no. (%) 0 1 (0.8) 0.46
Urinary tract infection, no. (%) 2 (3.0) 2 (1.6) 0.54
Surgical site infection, no. (%) 4 (6.0) 5 (4.1) 0.56
aNo source identiﬁed.
The values are in bold to highlight that they are statistically signiﬁcant.
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Management
Initial empirical antimicrobial therapy was ‘active’ in 38 of 67
(56.7%) C-patients and 55 of 122 (45.1%) NC-patients (p 0.13)
(Table 2). Empirical therapy included a glycopeptide in 33 of 67
(49.3%) C-patients and 23 of 122 (18.9%) NC-patients
(p <0.01). The time between arrival of the blood culture in
the laboratory and the time of the ﬁrst dose of glycopeptide
was signiﬁcantly shorter in C-patients than in NC-patients
(1 day (range 13–5 days) vs. 2 days (range 1–12 days),
respectively, p <0.01). Deﬁnitive antimicrobial therapy
included a glycopeptide in all cases, and the median duration
of therapy was 13 days (range 0–217 days) in C-patients, and
14 days (range 0–288 days) in NC-patients (p 0.09).
Outcome
The overall 7-day mortality rate was ﬁve of 67 (7.5%) in
C-patient episodes, and 23 of 122 (18.9%) in NC-patient
episodes (OR 0.35, 95% CI 0.13–0.96, p 0.04). At 30 days, the
all-cause mortality rate reached 15 of 67 (22.4%) and 38 of 122
(31.1%), respectively (OR 0.64, 95% CI 0.32–1.27, p 0.20).
Cox regression showed a 60% reduction in mortality in
C-patient episodes (risk difference 0.58, p <0.01) after
adjustment for SAPS-II, aboriginality, and whether active
therapy was given (Table 3).
Patients who received active empirical therapy had a lower
7-day mortality rate than those whose initial empirical therapy
was not active (9.7% vs. 19.8%, OR 0.43, 95% CI 0.19–1.0,
p 0.05). The difference was more marked at 30 days (19.4% vs.
36.5%, OR 0.42, 95% CI 0.22–0.81, p 0.01).
Discussion
This study shows that over one-third of patients with MRSA
bacteraemia are known to be colonized with this pathogen
when empirical therapy is initiated. Similar ﬁndings have been
reported previously: 75 of 287 (26.1%) patients with MRSA
bacteraemia had a documented history of MRSA colonization
or infection [11].
Less than half of C-patients received a glycopeptide as part
of their empirical therapy in this study. There are several
possible explanations for this. First, the Micro-Alert tag on the
patient’s identiﬁcation label is small, and clinicians are not
routinely educated as to the meaning of the Micro-Alert tag.
Indeed, this system was implemented for infection control
purposes, and was not designed to assist clinicians in patient
management. Second, glycopeptide use is heavily restricted at
our institution, and clinicians require pre-approval from a
microbiologist/infectious disease physician, which could have
further limited glycopeptide use.
This study showed that C-patients had a lower 7-day
all-cause mortality rate than NC-patients. Furthermore,
knowing that a patient was colonized remained a signiﬁcant
protective variable in our Cox regression analysis. As
C-patients were more likely than NC-patients to be empir-
ically treated with an antibiotic against which the isolate
tested susceptible in vitro, we postulate that this difference in
outcome may be related to the difference in the antimicrobial
therapy. These results add to the growing evidence that, in
the septic patient, active empirical therapy is associated with
a lower mortality rate than therapy without in vitro activity
against the isolated pathogen: Lodise et al. demonstrated that
S. aureus bacteraemia-attributable mortality was increased
when active therapy was delayed beyond 45 h after the blood
culture was taken [5]. Similar results have been published
from the USA [12] and Spain [13]. However, others have
failed to demonstrate a beneﬁt of early active therapy
[14,15]. These conﬂicting results may be attributable to
antibiotics other than glycopeptides not being considered as
appropriate antimicrobial therapy, despite having in vitro
activity [15], or an excessively long period (2 days) being
considered to be appropriate for the initiation of active
therapy [5,14].
TABLE 2. Initial ‘active’ empirical antimicrobial therapy
Antibiotic
Number of
episodes
Number (%) of
episodes in which
this antibiotic was
the single ‘active’ agent
Known to be colonized (n = 38)
Aminoglycoside 9 4 (44.4)a
Glycopeptide 33 28 (84.8)
Quinolone 2 0 (0)
Not known to be colonized (n = 55)
Aminoglycoside 27 22 (81.5)a
Clindamycin 1 0 (0)
Doxycycline 1 0 (0)
Glycopeptide 23 20 (86.9)
Macrolide 4 3 (75)
Quinolone 4 2 (50)
Rifampicin 2 0 (0)
Trimethoprim 1 0 (0)
ap 0.003 for comparison between episodes where patients are known to be
colonized and those where patients are not known to be colonized.
TABLE 3. Cox regression analysis
Independent variables Hazard ratio LCI95% UCI95% p
Micro-Alert (yes) 0.58 0.37 0.91 0.02
SAPS-II (standardized) 6.43 1.60 25.9 0.01
Aboriginal (yes vs. no) 0.40 0.22 0.74 <0.014
Effective treatment given,
SAPS-II (standardized)
0.26 0.07 1.00 0.05
LCI95%, Lower Conﬁdence Interval; SAPS, Simpliﬁed Acute Physiology Score;
UCI95%, Upper Conﬁdence Interval.
The model shows a 60% reduction in risk of death for C-patients (risk
difference 0.58, p 0.006) after adjustment for SAPS-II, Aboriginality, and whether
an effective therapy was given. There is an interaction between SAPS-II and
effective therapy that is incorporated in the adjustment.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 530–535
CMI Robinson et al. Prior MRSA colonization status and outcome from bacteraemia 533
An alternative explanation for the lower mortality rate
among C-patients could be the acquisition of protective
immunity to S. aureus. However, despite the generation of
speciﬁc antibodies after invasive infection, it has not been
established that this immune response results in protection
against re-infection [16]. Furthermore, capsular polysaccharide
vaccines, as well as virulence factor-based vaccines and
iron-binding protein-based vaccines, have so far failed to
demonstrate any reduction in invasive staphylococcal infection
[16]. In fact, for the latter, a trial had to be prematurely stopped
because of increased mortality among those who did develop
an invasive staphylococcal infection after immunization, without
any reduction of its incidence [17]. Nevertheless, cell-mediated
immunity may play a role, as patients with defects in T-cell
immunity, such as those with human immunodeﬁciency virus
infection or Job’s syndrome, experience recurrent and often
more severe cutaneous infections [16].
This study has important limitations. First, data were
collected retrospectively, and possible non-identiﬁed con-
founders may have skewed the data. Second, C-patients are
demographically different from NC-patients. Indeed, we have
found that patients known to be colonized are more likely to
be diabetic, to be on dialysis, to be aboriginal/Torres Strait
islanders, or to have had a hospitalization/outpatient clinic
visit in the past 12 months. However, if these variables did
affect our results, they should have increased mortality in the
C-patients, as diabetic or dialysis patients are known to have
increased mortality, and aboriginal/Torres Strait islanders
have a lower life-expectancy [18,19]. Despite these demo-
graphic differences, it is noteworthy that the severity of the
infections as measured by SAPS-II, the need for ICU
admission, the duration of fever, or the proportion of
patients with positive repeat blood cultures, was similar
between groups.
Universal MRSA screening on admission has been advocated
by some experts [20], and is now compulsory in some US
hospitals [21]. However, conﬂicting results have been
reported on the utility of this strategy. In a prospective
cross-over cohort study, Harbarth et al. failed to demonstrate
any reduction in nosocomial MRSA infections, possibly because
of the low baseline MRSA infection rate [22]. However,
Robicsek et al. showed, in an observational study over three
consecutive periods, that the introduction of universal MRSA
screening on admission was associated with a signiﬁcant
decrease in the prevalence of MRSA infections [23]. These
studies were aimed at assessing the usefulness of universal
MRSA screening for prevention of MRSA transmission, but
they did not investigate the impact of MRSA screening on
antimicrobial prescribing. Presurgical screening has been
effectively used to identify MRSA colonization, to allow either
decolonization prior to surgery or adjustment of perioperative
antimicrobial prophylaxis [24]. Our study demonstrates that
the lack of clinician awareness regarding the signiﬁcance of the
Micro-alert tag may be a correctable missed opportunity to
support appropriate decision-making in antimicrobial prescrib-
ing in septic patients. However, this strategy needs prospective
validation before it can be recommended to other hospitals, as
the systematic use of glycopeptides in patients known to be
colonized with MRSA but who ultimately do not have an
infection caused by MRSA may lead to unnecessary toxicity
and an increase in resistance. Whether a similar process may
be equally effective for other pathogens, such as vancomy-
cin-resistant enterococci and multiresistant Gram-negative
bacilli, needs to be determined. The use of a ‘microbiological
passport’, similar to the biological passport of some profes-
sional athletes, containing the results of previous colonization
or infection with multiresistant organisms, could be an
attractive strategy, and may help not only in reducing the
transmission of these pathogens, but also in improving the
initial management and outcome of septic patients.
Financial Disclosure
This research was supported by the Department of Microbi-
ology and Infectious Diseases, Royal Perth Hospital, Perth,
Australia.
Transparency Declaration
The authors declare no conﬂict of interests.
References
1. Robinson JO, Pearson JC, Christiansen KJ, Coombs GW, Murray RJ.
Community-associated versus healthcare-associated methicillin-resis-
tant Staphylococcus aureus bacteraemia: a 10-year retrospective review.
Eur J Clin Microbiol Infect Dis 2009; 28: 353–361.
2. Turnidge JD, Kotsanas D, Munckhof W et al. Staphylococcus aureus
bacteraemia: a major cause of mortality in Australia and New Zealand.
Med J Aust 2009; 191: 368–373.
3. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resis-
tant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust
2001; 175: 264–267.
4. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer
AW, Carmeli Y. Comparison of mortality associated with methicil-
lin-resistant and methicillin-susceptible Staphylococcus aureus bactere-
mia: a meta-analysis. Clin Infect Dis 2003; 36: 53–59.
5. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of
delayed antibiotic treatment for hospital-acquired Staphylococcus aureus
bacteremia. Clin Infect Dis 2003; 36: 1418–1423.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 530–535
534 Clinical Microbiology and Infection, Volume 20 Number 6, June 2014 CMI
6. Paul M, Kariv G, Goldberg E, et al. Importance of appropriate empirical
antibiotic therapy for methicillin-resistant Staphylococcus aureus bacter-
aemia. J Antimicrob Chemother 2010; 65: 2658–2665.
7. Boyce JM. MRSA patients: proven methods to treat colonization and
infection. J Hosp Infect 2001; 48(suppl A): S9–S14.
8. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus
infection after previous infection or colonization. Clin Infect Dis 2003;
36: 281–285.
9. Le Gall JR, Lemeshow S, Saulnier F. A new simpliﬁed acute physiology
score (SAPS II) based on a European/North American multicenter
study. JAMA 1993; 270: 2957–2963.
10. Li JS, Sexton DJ, Mick N et al. Proposed modiﬁcations to the Duke
criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;
30: 633–638.
11. Schweizer ML, Furuno JP, Harris AD et al. Clinical utility of infection
control documentation of prior methicillin-resistant Staphylococcus
aureus colonization or infection for optimization of empirical antibiotic
therapy. Infect Control Hosp Epidemiol 2008; 29: 972–974.
12. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB.
Impact of initial antibiotic choice and delayed appropriate treatment on
the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol
Infect Dis 2006; 25: 181–185.
13. Rodriguez-Bano J, Millan AB, Dominguez MA et al. Impact of inappro-
priate empirical therapy for sepsis due to health care-associated
methicillin-resistant Staphylococcus aureus. J Infect 2009; 58: 131–137.
14. Kim SH, Park WB, Lee KD et al. Outcome of inappropriate initial
antimicrobial treatment in patients with methicillin-resistant
Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004; 54:
489–497.
15. Fang CT, Shau WY, Hsueh PR et al. Early empirical glycopeptide
therapy for patients with methicillin-resistant Staphylococcus aureus
bacteraemia: impact on the outcome. J Antimicrob Chemother 2006; 57:
511–519.
16. Spellberg B, Daum R. Development of a vaccine against Staphylococcus
aureus. Semin Immunopathol 2012; 34: 335–348.
17. Fowler VG, Allen KB, Moreira ED et al. Effect of an investigational
vaccine for preventing Staphylococcus aureus infections after cardiotho-
racic surgery: a randomized trial. JAMA 2013; 309: 1368–1378.
18. Gu K, Cowie CC, Harris MI. Mortality in adults with and without
diabetes in a national cohort of the US population, 1971–1993. Diabetes
Care 1998; 21: 1138–1145.
19. Freemantle CJ, Read AW, de Klerk NH, McAullay D, Anderson IP,
Stanley FJ. Patterns, trends, and increasing disparities in mortality for
aboriginal and non-aboriginal infants born in Western Australia, 1980–
2001: population database study. Lancet 2006; 367: 1758–1766.
20. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Committee tHICPA.
Management of multidrug-resistant organisms in healthcare settings, 2006.
Atlanta. 2006. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ar/
mdroGuideline2006.pdf (last accessed 14 February 2013).
21. Assembly IG (210 ILCS 83/). MRSA screening and reporting act.
Springﬁeld, 2007. Available at: http://www.ilga.gov/legislation/ilcs/ilcs3.
asp?ActID=2919&ChapAct=210%A0ILCS%A083/&ChapterID=21&Ch
apterName=HEALTH%20FACILITIES&ActName=MRSA%20Screening
%20and%20Reporting%20Act (last accessed 14 February 2013).
22. Harbarth S, Fankhauser C, Schrenzel J et al. Universal screening for
methicillin-resistant Staphylococcus aureus at hospital admission and
nosocomial infection in surgical patients. JAMA 2008; 299: 1149–
1157.
23. Robicsek A, Beaumont JL, Paule SM et al. Universal surveillance for
methicillin-resistant Staphylococcus aureus in 3 afﬁliated hospitals. Ann
Intern Med 2008; 148: 409–418.
24. Jog S, Cunningham R, Cooper S et al. Impact of preoperative screening
for meticillin-resistant Staphylococcus aureus by real-time polymerase
chain reaction in patients undergoing cardiac surgery. J Hosp Infect
2008; 69: 124–130.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 530–535
CMI Robinson et al. Prior MRSA colonization status and outcome from bacteraemia 535
